Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

924P - BLEACH&STAIN, a novel multiplex fluorescence immunohistochemistry framework that facilitates a fast high-throughput analysis of >15 biomarkers in more than 3000 human carcinomas

Date

10 Sep 2022

Session

Poster session 10

Topics

Cancer Biology;  Tumour Immunology;  Pathology/Molecular Biology;  Molecular Oncology

Tumour Site

Breast Cancer

Presenters

Elena Bady

Citation

Annals of Oncology (2022) 33 (suppl_7): S417-S426. 10.1016/annonc/annonc1061

Authors

E. Bady1, K. Möller1, N.F. Debatin1, T. Mandelkow1, C. Hube-Magg1, N.C. Blessin2

Author affiliations

  • 1 Pathology, University Medical Center Hamburg-Eppendorf, 20246 - Hamburg/DE
  • 2 Institute Of Pathology, University Medical Center Hamburg-Eppendorf, 20246 - Hamburg/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 924P

Background

Multiplex fluorescence immunohistochemistry (mfIHC) approaches were yet either limited to 6 markers or limited to a small (1.5cmx1.5cm) tissue size that hampers translational studies on large tissue microarray (TMA) cohorts.

Methods

To assess more markers in a large patient cohort, we have developed a BLEACH&STAIN mfIHC approach that enables the analysis of ≥15 biomarkers in 3098 tumor samples from 44 different carcinoma entities within one week and without costly instrumentalization. An artificial intelligence-based framework – incorporating three different deep learning systems – for automated marker quantification was used to interoperate the BLEACH&STAIN data.

Results

This approach was used to study the relationship between PD-L1 expression on multiple different cell types and the relationship with various leucocyte subtypes (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, CD31). Comparing the automated and deep learning-based BLEACH&STAIN PD-L1 analysis framework with conventional brightfield PD-L1 data revealed a high concordance in tumor cells (p<0.0001) as well as immune cells (p<0.0001) and an accuracy of our approach ranging from 90% to 95.2%. Unsupervised clustering showed that a major proportion of the three PD-L1 phenotypes (i.e., PD-L1+ tumor and immune cells [G1], PD-L1+ immune cells [G2], PD-L1 negative [G3]) were either inflamed (G1.1, G2.1, G3.1) or non-inflamed (G1.2, G2.2, G3.2) and showed distinct spatial orchestration patterns.

Conclusions

BLEACH&STAIN mfIHC in combination with a deep learning-based framework for automated PD-L1 assessment on tumor and immune cells enabled a rapid and comprehensive assessment of 15 biomarkers across more than 3000 tumor entities that is quick and easy to establish in all laboratories. In breast cancer, the PD-L1 relative expression on tumor cells showed a significantly higher predictive performance for overall survival compared to the commonly used PD-L1 tumor proportion score.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.